Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas

May 8, 2023

Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it...

Read more

Stamford Pharmaceuticals Inc announces amendment and expansion of the ASN-002-003 Phase 2a Study in BCNS and sporadic BCC subjects with up to an addition 5 arms.

April 14, 2023

Stamford Pharmaceuticals Inc, today announced the expansion of its ASN-002-003 Phase 2A study (NCT 04416516). The study performed in collaboration...

Read more